Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "technology"

2523 News Found

Sai Life Sciences to hire 700+ professionals to support expansion
News | February 24, 2026

Sai Life Sciences to hire 700+ professionals to support expansion

One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree


UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction
News | February 24, 2026

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences


Novo Nordisk’s
Clinical Trials | February 24, 2026

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies


Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion
Hospitals | February 23, 2026

Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion

The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore


PharmEasy integrates with Samsung Health to streamline digital healthcare
Digitisation | February 23, 2026

PharmEasy integrates with Samsung Health to streamline digital healthcare

Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership


Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator
Healthcare | February 22, 2026

Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator

Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them


Lonza scales bioconjugate innovation through enhanced synthesis offering
News | February 21, 2026

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization


FDA accepts Teva’s NDA for long-acting schizophrenia injection
Drug Approval | February 21, 2026

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations